Literature reviews  >  Articles for review > West et al Performance of the rapid plasma... 

 

About SDI
Mission
Diagnostic
Priorities
Workplan
Activities
Newsletters
Grants
Publications
Journal articles
Guidelines
Manuals
Reports
Literature reviews
Contact us

Rapid plasma reagin and rapid syphilis screening tests do not perform well for the diagnosis of syphilis in field conditions.

Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of syphilis in field conditions in rural Africa.
West B, Walraven G, Morison L, Brouwers J, Bailey R.
Sex Transm Infect. 2002;78:282-285

 

Summary:

Question
How well do the rapid plasma reagin (RPR) test and a new rapid syphilis test (RST) perform in the field as primary screening methods for syphilis?

Design
Serum samples were collected and tested for syphilis seropositivity in temporary field laboratories using an RPR and an RST strip. The results of the field tests were compared to those obtained using a repeat RPR and a TPHA test carried out in a standard laboratory.

Participants
A total of 1325 women, aged 15-54, who participated in a large community-based reproductive health survey in 20 villages in the Gambia were tested.

Description of Tests and Diagnostic Standard
Sera were tested on site, immediately following collection, by two syphilis screening tests: 1) a standard RPR 18 mm circle card test (Quorum Diagnostics, Vancouver, BC, Canada) using one drop of sample and mixing for 8 minutes, and 2) a one step immunochromatographic strip test utilizing a 47 kDa recombinant antigen of T. pallidum (RST, Quorum Diagnostics) according to the manufacturer's guidelines. At the end of each day, samples were transported to a permanent, well-equipped laboratory, frozen, and tested within one week by RPR and TPHA (Fujirebio, Mast Laboratories, UK) using standard techniques. The same laboratory assistant performed the tests in the field and in the laboratory. A diagnosis of "active" syphilis was defined as laboratory RPR and TPHA positive.

Main Outcome Measures
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of field RPR and RST tests were calculated for the detection of cases of "active" syphilis as determined by the results of samples tested in the laboratory by RPR and TPHA.

Main Results
The performance of the field RPR and RST tests against serologically active syphilis (defined by laboratory RPR positive and TPHA positive) is shown in the table. In the laboratory, 40 (3.0 %) of 1325 serum samples were RPR and TPHA positive. In a direct comparison of RPR results on 1295 samples tested both in the field and in the laboratory, there was agreement on 1207 negative and 35 positive samples, while 41 samples were positive in the field but negative in the laboratory and 12 were negative in the field and positive in the laboratory. A comparison of the results of 1325 samples tested with RST and TPHA, which both use T. pallidum antigens, showed agreement on 1204 negative and 51 positive samples, while 41 samples were positive by RST and negative by TPHA and 29 were negative by RST and positive by TPHA.

Performance of field RPR and rapid syphilis tests in defining cases of "active" syphilis
Test Number tested Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Field RPR 1295 77.5 96.4 40.8 99.3
Rapid syphilis test 1325 75.0 95.2 32.6 99.2

Authors' Conclusions
The new RST was easier to use and interpret than the RPR test and performed similarly as a field screening test. However, neither test predicted well the presence of active syphilis in this low prevalence population. The data suggest that in a higher prevalence population (10-15%), where laboratory facilities are limited, a positive test for either field RPR testing or RST would imply a 65-80% probability of active syphilis. In this case, 3-4% of subjects with a negative test would escape detection.

Source of funding: Medical Research Council, and Quorum Diagnostics, Ltd.

For correspondence: B. West, MRC Laboratories, PO Box 273, Banjul, Gambia. E-mail address: bwest@mrc.gm

   

about SDI | newsletters | grants | publications | literature reviews

WHO Home - WHO Search - TDR Home - SDI Home - SDI Contact us
(c) WHO/OMS 2001